Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144649 | 0.81 | DCUN1D1 (0.50) | TACR1 | |
| Hydrochloric Acid SCHEMBL4146160 | 0.80 | DCUN1D1 (0.49) | TACR1 | |
| SCHEMBL4131432 | 0.79 | STS (0.57) | STSJAK2JAK1KDM4EPKM | |
| SCHEMBL2920158 | 0.77 | STS (0.62) | STSTACR1TGFBR1KDM4EPKM | |
| SCHEMBL2960832 | 0.76 | STS (0.52) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL3012474 | 0.74 | JAK2 (0.62) | STSJAK2JAK1KDM4EPKM | |
| SCHEMBL4306665 | 0.73 | MEN1 (0.51) | STSTACR1JAK2JAK1TGFBR1 | |
| SCHEMBL4306235 | 0.73 | MEN1 (0.53) | STSTACR1JAK2JAK1TGFBR1 | |
| SCHEMBL803527 | 0.73 | JAK2 (0.74) | STSJAK2JAK1KDM4EPKM | |
| SCHEMBL7803789 | 0.72 | KDM4E (0.69) | STSTACR1TGFBR1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | LEHR PHILIPP | 2009-02-12 | — | — | US | disclosed |
| US-7439362-B2 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2008-10-21 | — | — | US | disclosed |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1492782-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082842-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | STS 1/4885TACR1 1098/4885JAK2 1860/4885 |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SELENOI, SULT2A1 | STS 1/4885TACR1 1430/4885JAK2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.